MicroPort NeuroTech Ltd (2172) Fair Value & Analysis
Healthcare · HK · Market cap HK$6.2B
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 3 days ago
Fair value updated Aug 13, 2026, revised from HK$8.08 to HK$8.09 (+0.1%) since Aug 5, 2026. Share price −4.6% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from HK$6.07 (bear) to HK$10.11 (bull), base HK$8.09. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 70/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
49‑month range HK$6.05 – HK$25.02 · fair‑value band HK$6.07 – HK$10.11 · the HK$8.77 price screens above the HK$8.09 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
MicroPort NeuroTech Ltd (2172) currently trades at HK$8.77, while our model-based Fair Value estimate is HK$8.09, implying the stock looks roughly 7.8% fairly valued today. The Quality Score stands at 70/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, MicroPort NeuroTech Ltd generated revenue of HK$790M at a net margin of 23.3%. Revenue grew 15.3% year over year. It earns a return on equity of 10.5%. The balance sheet holds a net cash position of HK$596M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$6.07 (bear case) to HK$10.11 (bull case); at HK$8.77, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 46% below its 52-week high and 5% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at -8%, 2172 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (HK$10.15) versus Asset-Based (HK$2.12). Highest evidence: Growth DCF (80).
Notify me when 2172 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 68 · Market factors (momentum, volatility) 28
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
MicroPort NeuroScientific Corporation provides neuro-interventional medical devices. The company provides NUMEN Silk, a electronically detachable coil; Numen Lighting, a coil embolization system; Numen Nest, a detachable coil; NuFairy absorbable coil embolization system; Tubridge, a flow-diverting stent; Tubridge Plus, a flow-diverting stent; WILLIS, a …
Full company description
MicroPort NeuroScientific Corporation provides neuro-interventional medical devices. The company provides NUMEN Silk, a electronically detachable coil; Numen Lighting, a coil embolization system; Numen Nest, a detachable coil; NuFairy absorbable coil embolization system; Tubridge, a flow-diverting stent; Tubridge Plus, a flow-diverting stent; WILLIS, a intracranial stent graft system; Comaneci, a embolization assist device; and Rebridge, an intracranial visualized stent for intracranial aneurysm, as well as liquid embolic agent for cerebral arteriovenous malformations. It also offers APOLLO intracranial stent system for intracranial atherosclerosis; Bridge rapamycin target eluting and Bridge MAX rapamycin target eluting vertebral artery stent system for vertebral artery stenosis; Diveer intracranial balloon dilatation catheter, intracranial drug-coated balloon catheter system, intracranial self-expanding rapamycin target eluting stent, and intracranial balloon-expandable rapamycin target eluting stent for intracranial stenosis; and Carotid stent system, Safecer embolic protection device, and PathFinder carotid balloon dilation catheter for carotid artery stenosis. In addition, the company provides NeuroHawk thrombectomy device, NeuroHawk pass17/21 and medibox thrombectomy device and accessories, Tigertriever revascularization device, WAVE-track intracranial aspiration catheter, X-track intracranial distal access catheter, and NeuroGuard neurovascular balloon guide catheter for acute ischemic stroke. Further, it offers U-track intracranial support catheter system, Fastrack microcatheter system, QUEEN-track and 17 Microcatheter, Veyronwire neurovascular guide wire, Sheathru delivery catheter, and filter extension tube for single use. The company was founded in 2004 and is headquartered in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
MicroPort NeuroTech Ltd reported revenue of HK$770M in FY2025 versus HK$383M in FY2021, a compound +19.1%/yr. Reported net income was HK$180M in FY2025, compounding +65.1%/yr from FY2021.
Watch 2172: get an alert when its fair value changes →
Peer Group
Medical Devices · 350 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $110.91 | $74.79 | -33% |
| Stryker Corporation SYK | $347.21 | $186.28 | -46% |
| Medtronic plc MDT | $90.76 | $65.57 | -28% |
| Boston Scientific Corporation BSX | $51.42 | $38.44 | -25% |
| Edwards Lifesciences Corporation EW | $93.05 | $41.02 | -56% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.60 | ¥147.63 | -4% |
| Shanghai United Imaging Healthcare Co 688271 | ¥110.50 | ¥43.60 | -61% |
| Demant A/S DEMANT | kr 289.60 | kr 161.17 | -44% |
| Getinge AB GETIB | kr 239.30 | kr 192.14 | -20% |
| Sectra AB SECTB | kr 280.00 | kr 66.81 | -76% |
Compare MicroPort NeuroTech Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is MicroPort NeuroTech Ltd (2172) overvalued or undervalued?
What is the fair value of 2172?
What is the quality score of 2172?
What is the revenue of MicroPort NeuroTech Ltd (2172)?
What is the net profit margin of 2172?
Does MicroPort NeuroTech Ltd pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track MicroPort NeuroTech Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.